Answers are grounded in this paper and cite their sources.
Uncovers how gamma-delta T cells drive neuroinflammation and alter cognitive function in Alzheimer’s disease models, suggesting new treatment avenues.
Introduction Neuroinflammation is a central feature of Alzheimer’s disease (AD), driving neuronal injury, synaptic dysfunction, and the accumulation of amyloid plaques and neurofibrillary tangles. In AD, microglia transition from a homeostatic (M0) to a neurodegenerative (MGnD) phenotype that promotes recruitment of peripheral immune cells to the brain. We identified γδ T cells as key modulators of this process. Methods We used flow cytometry, IF, and behavioral testing in APP/PS1Jucker and APP/PS1:γδ⁻/⁻ mice to assess immune infiltration, cytokine production, microglial phenotypes, and cognition; photoconversion and cell tracking in APP/PS1:Kaede mice to trace gut- and lymphoid-derived γδ T cells; and single-cell RNA sequencing of PBMCs and brain tissues from AD patients to profile γδ T cell transcriptional programs. Results In the APP/PS1Jucker model, γδ T cells infiltrated the brain by 3 months of age - preceding CD8+ T cell recruitment - and correlated with the emergence of an MGnD microglial signature. Infiltrating Vγ1 cells predominantly produced IFN-γ, while Vγ4 cells secreted IL-17. γδ T cell deficiency improved cognition, reduced amyloid deposition, shifted microglia toward a homeostatic phenotype, and diminished CD8+ T cell infiltration. Using photoconvertible APP/PS1:Kaede mice, we demonstrated that gut-derived Vγ4 γδ T cells preferentially migrate to the brain, supporting a microbiota-dependent gut—brain axis, whereas Vγ1 cells originate from lymphoid organs. Single-cell RNA sequencing of PBMCs and brains from AD patients revealed γδ T cell enrichment for IFN-γ and IL-17 transcriptional programs, mirroring mouse data. Conclusion Together, these findings uncover a pathogenic γδ T cell—microglia—CD8+ T cell axis linking gut immunity to neuroinflammation, identifying γδ T cells and their cytokines as promising therapeutic targets for AD.
No takes yet. Share an insight, caveat, or question.
Rezende et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: